Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion
Information source: Shaheed Beheshti Medical University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Branch Retinal Vein Occlusion
Intervention: Triamcinolone (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Shaheed Beheshti Medical University Official(s) and/or principal investigator(s):
Alireza Ramezani, MD, Principal Investigator, Affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
Summary
The purpose of this study is to determine whether intraocular injection of triamcinolone is
effective in the treatment of macular edema in acute branch retinal vein occlusion.
Clinical Details
Study design: Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Central macular thickness
Secondary outcome: Visual acuityRetinal neovascularization Intraocular pressure Cataract progression
Detailed description:
Intravitreal triamcinolone has recently been shown to have beneficial effect on chronic
macular edema due to vein occlusion and preventive effect on neovascularization.
Hypothetically, prevention of macular derangement by reducing the amount of edema from early
phase after occlusion until restoration of collaterals seems to be helpful in these eyes. To
our knowledge, no prospective randomized clinical trial, considering both macular changes and
preventive effect on neovascularization has been published for intravitreal triamcinolone in
acute branch retinal vein occlusion.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Eyes suffering from branch retinal vein occlusion with less than 2 months duration.
Exclusion Criteria:
- Monocularity,
- Previous intraocular surgery or laser therapy
- Glaucoma or ocular hypertension
- Significant media opacity
- Existence of traction on the macula
- Visual acuity ≥20/40
- Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)
Locations and Contacts
Alireza Ramezani, MD, Tehran 16666, Iran, Islamic Republic of
Additional Information
Starting date: February 2003
Ending date: December 2007
Last updated: June 16, 2008
|
